165 related articles for article (PubMed ID: 28500634)
1. Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel.
Kim M; Kim J; Jeong SW; Jo H; Woo YR; Park HJ
Exp Dermatol; 2017 Nov; 26(11):1143-1145. PubMed ID: 28500634
[TBL] [Abstract][Full Text] [Related]
2. Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions.
Oon HH; Lim ZV
Australas J Dermatol; 2017 Feb; 58(1):63-64. PubMed ID: 26763464
[TBL] [Abstract][Full Text] [Related]
3. Facial Dermatitis and Rosacea.
Fowler JF
Semin Cutan Med Surg; 2016 Jun; 35(6 Suppl):S107-9. PubMed ID: 27537212
[TBL] [Abstract][Full Text] [Related]
4. [Brimonidine (Mirvaso), dermal use].
Van Genechten D
J Pharm Belg; 2015 Jun; (2):45-6. PubMed ID: 26466509
[No Abstract] [Full Text] [Related]
5. Brimonidine tartrate gel plus topical steroid for the prevention of laser therapy-related postinflammatory hyperpigmentation.
Hong JY; Lee HW; Park KY; Kim BJ; Kim MN
Dermatol Ther; 2018 Sep; 31(5):e12657. PubMed ID: 30028559
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function.
Bertino B; Blanchet-Réthoré S; Thibaut de Ménonville S; Reynier P; Méhul B; Bogouch A; Gamboa B; Dugaret AS; Zugaj D; Petit L; Roquet M; Piwnica D; Vial E; Bourdès V; Voegel JJ; Nonne C
Exp Dermatol; 2018 Dec; 27(12):1378-1387. PubMed ID: 30290018
[TBL] [Abstract][Full Text] [Related]
7. MIRVASO (brimonidine tartrate) topical gel 0.33%.
Abramovits W; Prato A; Vincent KD; Scheinfeld N; Gupta AK
Skinmed; 2014; 12(1):41-3. PubMed ID: 24720083
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
9. Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy.
Gerber PA
Br J Dermatol; 2016 Jun; 174(6):1422-3. PubMed ID: 26727630
[No Abstract] [Full Text] [Related]
10. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
Steinhoff M; Schmelz M; Schauber J
Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
[TBL] [Abstract][Full Text] [Related]
11. Severe erythematotelangiectatic rosacea with cold wave-induced epidermal necrosis treated with carvedilol combined with brimonidine gel.
Lee CN; Lee JY
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28585298
[No Abstract] [Full Text] [Related]
12. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
[TBL] [Abstract][Full Text] [Related]
13. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
Lowe E; Lim S
J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
[TBL] [Abstract][Full Text] [Related]
15. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
Urban J; Siripunvarapon AH; Meekings A; Kalowitz A; Markowitz O
J Drugs Dermatol; 2014 Jul; 13(7):821-6. PubMed ID: 25007365
[TBL] [Abstract][Full Text] [Related]
16. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
17. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
[TBL] [Abstract][Full Text] [Related]
18. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
19. Rosacea First-choice treatments.
Prescrire Int; 2017 May; 26(182):126-128. PubMed ID: 30730673
[No Abstract] [Full Text] [Related]
20. Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors.
Hsia E; Tian M; Gil D
Exp Dermatol; 2018 Jul; 27(7):763-768. PubMed ID: 29637626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
